Compare CALX & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CALX | EVO |
|---|---|---|
| Founded | 1999 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 568.6M |
| IPO Year | 2009 | 2007 |
| Metric | CALX | EVO |
|---|---|---|
| Price | $33.56 | $1.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $66.50 | $7.00 |
| AVG Volume (30 Days) | ★ 875.7K | 143.7K |
| Earning Date | 04-21-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 157.78 | N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $510,367,000.00 | N/A |
| Revenue This Year | $16.40 | $1.37 |
| Revenue Next Year | $13.75 | $10.05 |
| P/E Ratio | $78.51 | ★ N/A |
| Revenue Growth | ★ 11.24 | N/A |
| 52 Week Low | $32.35 | $1.50 |
| 52 Week High | $71.22 | $4.27 |
| Indicator | CALX | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 27.85 | 38.78 |
| Support Level | N/A | $1.50 |
| Resistance Level | $40.76 | $1.97 |
| Average True Range (ATR) | 1.00 | 0.06 |
| MACD | -0.18 | 0.00 |
| Stochastic Oscillator | 15.21 | 42.59 |
Calix Inc develops, markets and sells its appliance-based platform, cloud and managed services that enable service providers of all types and sizes to innovate and transform their businesses. The company's customers utilize the real-time data and insights from Calix platforms to simplify their business and deliver experiences that excite their subscribers. The resulting growth in subscriber acquisition, loyalty and revenue creates more value for their businesses and communities. The Company's revenue is principally derived in the United States and it also has its presence in Europe, Americas excluding U.S., and Rest of World.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.